We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+3.83%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.15B
AUM Growth
-$403M
Cap. Flow
-$229M
Cap. Flow %
-3.73%
Top 10 Hldgs %
39.96%
Holding
178
New
9
Increased
64
Reduced
62
Closed
12

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$35.2M
2
SYK icon
Stryker
SYK
+$32.7M
3
UNH icon
UnitedHealth
UNH
+$27.9M
4
PODD icon
Insulet
PODD
+$25.5M
5
RMD icon
ResMed
RMD
+$25.5M

Top Sells

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$56.7M
2
ARGX icon
argenx
ARGX
+$45.6M
3
INSM icon
Insmed
INSM
+$43.4M
4
BSX icon
Boston Scientific
BSX
+$42.4M
5
HUM icon
Humana
HUM
+$36.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
2 Industrials 0.05%
3 Communication Services 0.02%
4 Technology 0.02%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AZN icon
101
AstraZeneca
AZN
$262B
$3.29M 0.05%
21,100
+9,500
+82% +$1.43M
WAY
102
Waystar Holding Corp
WAY
$4.27B
$3.23M 0.05%
+150,000
New +$3.25M
CAH icon
103
Cardinal Health
CAH
$53.5B
$3.2M 0.05%
32,582
+29,582
+986% +$3.01M
RXRX icon
104
Recursion Pharmaceuticals
RXRX
$1.56B
$3.19M 0.05%
425,810
+561
+0.1% +$4.89K
ACCD
105
DELISTED
Accolade Inc
ACCD
$3.02M 0.05%
842,577
-3,961,937
-82% -$30M
OM icon
106
Outset Medical
OM
$77.9M
$2.94M 0.05%
50,853
+12,696
+33% +$622K
GILD icon
107
Gilead Sciences
GILD
$167B
$2.67M 0.04%
38,934
+5,629
+17% +$376K
TDOC icon
108
Teladoc Health
TDOC
$1.7B
$2.67M 0.04%
272,798
– –
TEVA icon
109
Teva Pharmaceuticals
TEVA
$37.3B
$2.52M 0.04%
154,770
+12,557
+9% +$193K
PFE icon
110
Pfizer
PFE
$143B
$2.48M 0.04%
88,614
+54,780
+162% +$1.51M
DOCS icon
111
Doximity
DOCS
$3.87B
$2.02M 0.03%
72,155
-71,910
-50% -$1.9M
RDY icon
112
Dr. Reddy's Laboratories
RDY
$10.5B
$1.78M 0.03%
116,640
-87,840
-43% -$1.26M
MTEM
113
DELISTED
Molecular Templates, Inc.
MTEM
$1.47M 0.02%
1,279,820
+250,000
+24% +$370K
BIIB icon
114
Biogen
BIIB
$30.4B
$1.37M 0.02%
5,902
-106
-2% -$23K
CERT icon
115
Certara
CERT
$1.08B
$1.33M 0.02%
95,924
– –
CVS icon
116
CVS Health
CVS
$137B
$1.3M 0.02%
22,066
– –
EHC icon
117
Encompass Health
EHC
$11.1B
$1.19M 0.02%
13,868
-1,112
-7% -$93.3K
JNJ icon
118
Johnson & Johnson
JNJ
$609B
$1.14M 0.02%
7,797
+1,377
+21% +$205K
NVRO
119
DELISTED
NEVRO CORP.
NVRO
$1.14M 0.02%
135,235
– –
GOOG icon
120
Alphabet (Google) Class C
GOOG
$4.22T
$1.1M 0.02%
6,000
– –
PCVX icon
121
Vaxcyte
PCVX
$8.12B
$1.07M 0.02%
14,210
+966
+7% +$65.8K
CYTK icon
122
Cytokinetics
CYTK
$10.9B
$903K 0.01%
16,659
+1,019
+7% +$61.5K
KRYS icon
123
Krystal Biotech
KRYS
$10.5B
$771K 0.01%
4,198
-612
-13% -$103K
THC icon
124
Tenet Healthcare
THC
$16.8B
$720K 0.01%
5,414
+1,170
+28% +$141K
MRUS
125
DELISTED
Merus
MRUS
$580K 0.01%
9,800
– –
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2024 Portfolio in Review

As of Q2 2024, Bellevue Group held 178 positions worth $6.15B, down 6.1% from $6.56B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Bellevue Group withdrew a net $229M in Q2 2024, closing 12 positions and reducing 62 holdings. Its most notable exit was Shockwave Medical, Inc. Common Stock, an estimated $34.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials and Communication Services.

Against the trend, Bellevue Group opened a new position in Edgewise Therapeutics worth $25.7M.

  • Bellevue Group's largest Q2 2024 buy was Edgewise Therapeutics: 1,428,929 shares worth $25.7M.
  • Bellevue Group added most to Biohaven in Q2 2024, an estimated $35.2M increase.
  • Bellevue Group's biggest Q2 2024 reduction was Intuitive Surgical, cutting an estimated $56.7M.
  • Bellevue Group fully exited Shockwave Medical, Inc. Common Stock in Q2 2024, selling an estimated $34.4M.
  • Bellevue Group's ten largest holdings make up 40% of its $6.15B portfolio in Q2 2024.
  • Bellevue Group opened 9 new positions and closed 12 in Q2 2024.
  • Bellevue Group's portfolio value fell 6.1% quarter-over-quarter to $6.15B.

Based on Bellevue Group's 13F filing for Q2 2024, filed 14 Aug 2024.